Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial.

Abstract

CONTEXT:

Coronary artery bypass graft (CABG) surgery with autologous vein grafting is commonly performed. Progressive neointimal hyperplasia, however, contributes to considerable vein graft failure. Edifoligide is an oligonucleotide decoy that binds to and inhibits E2F transcription factors and thus may prevent neointimal hyperplasia and vein graft failure.

OBJECTIVE:

To assess the efficacy and safety of pretreating vein grafts with edifoligide for patients undergoing CABG surgery.

DESIGN, SETTING, AND PARTICIPANTS:

A phase 3 randomized, double-blind, placebo-controlled trial of 3014 patients undergoing primary CABG surgery with at least 2 planned saphenous vein grafts and without concomitant valve surgery, who were enrolled between August 2002 and October 2003 at 107 US sites.

INTERVENTION:

Vein grafts were treated ex vivo with either edifoligide or placebo in a pressure-mediated delivery system. The first 2400 patients enrolled were scheduled for 12- to 18-month follow-up angiography.

MAIN OUTCOME MEASURES:

The primary efficacy end point was angiographic vein graft failure (> or =75% vein graft stenosis) occurring 12 to 18 months after CABG surgery. Other end points included other angiographic variables, adverse events through 30 days, and major adverse cardiac events.

RESULTS:

A total of 1920 patients (80%) either died (n = 91) or underwent follow-up angiography (n = 1829). Edifoligide had no effect on the primary end point of per patient vein graft failure (436 [45.2%] of 965 patients in the edifoligide group vs 442 [46.3%] of 955 patients in the placebo group; odds ratio, 0.96 [95% confidence interval {CI}, 0.80-1.14]; P = .66), on any secondary angiographic end point, or on the incidence of major adverse cardiac events at 1 year (101 [6.7%] of 1508 patients in the edifoligide group vs 121 [8.1%] of 1506 patients in the placebo group; hazard ratio, 0.83 [95% CI, 0.64-1.08]; P = .16).

CONCLUSIONS:

Failure of at least 1 vein graft is quite common within 12 to 18 months after CABG surgery. Edifoligide is no more effective than placebo in preventing these events. Longer-term follow-up and additional research are needed to determine whether edifoligide has delayed beneficial effects, to understand the mechanisms and clinical consequences of vein graft failure, and to improve the durability of CABG surgery. Clinical Trial Registration ClinicalTrials.gov Identifier: NCT00042081.

• Authors: John H Alexander, Gail Hafley, Robert A Harrington, Eric D Peterson, T Bruce Ferguson Jr, Todd J Lorenz, Abhinav Goyal, Michael Gibson, Michael J Mack, Daniel Gennevois, Robert M Califf, Nicholas T Kouchoukos, PREVENT IV Investigators
• Journal: JAMA (JAMA) Vol. 294 Issue 19 Pg. 2446-54 (Nov 16 2005) ISSN: 1538-3598 [Electronic] United States
• PMID: 16287955 (Publication Type: Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• E2F Transcription Factors
• Oligonucleotides
• edifoligide
• DNA

Topics

• Aged
• Angiography
• Coronary Artery Bypass
• DNA (therapeutic use)
• Double-Blind Method
• E2F Transcription Factors
• Female
• Genetic Therapy (methods)
• Graft Occlusion, Vascular (prevention & control)
• Humans
• Hyperplasia
• Male
• Middle Aged
• Oligonucleotides (therapeutic use)
• Saphenous Vein (diagnostic imaging, drug effects, pathology, transplantation)
• Survival Analysis
• Tissue and Organ Harvesting
• Transfection
• Transplantation, Autologous
• Transplants
• Vascular Patency (drug effects)